

GLAXOSMITHKLINE PLC  
Form 6-K  
October 11, 2013

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending October 2013

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging  
Managerial Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan (the Plan) notified the Company and the under-mentioned persons on 11 October 2013 of the following increases in their notional interests in Ordinary Shares and American Depositary Shares (ADSs) at a price of 1546.50 pence per Ordinary Share and \$50.22 per ADS following the re-investment of dividends paid to shareholders on 3 October 2013.

Sir Andrew Witty      Acquisition of 1,417 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 1,417 Ordinary Shares under the matching element of the Plan (Company contribution).

Mr S Dingemans      Acquisition of 508 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 508 Ordinary Shares under the matching element of the Plan (Company contribution).

Dr M M Slaoui        Acquisition of 647 ADSs under the personal contribution element of the Plan.

Acquisition of 647 ADSs under the matching element of the Plan (Company contribution).

Mr S M Bicknell      Acquisition of 213 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 213 Ordinary Shares under the matching element of the Plan (Company contribution).

Mrs D P Connelly      Acquisition of 115 ADSs under the personal contribution element of the Plan.

Acquisition of 115 ADSs under the matching element of the Plan (Company contribution).

Mr R G Connor        Acquisition of 58 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 58 Ordinary Shares under the matching element of the Plan (Company contribution).

Mr W C Louv          Acquisition of 95 ADSs under the personal contribution element of the Plan.

Acquisition of 95 ADSs under the matching element of the Plan (Company contribution).

Mr D S Redfern      Acquisition of 335 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 335 Ordinary Shares under the matching element of the Plan (Company contribution).

Ms C Thomas        Acquisition of 215 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 215 Ordinary Shares under the matching element of the Plan (Company contribution).

Mr P C Thomson    Acquisition of 11 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 11 Ordinary Shares under the matching element of the Plan (Company contribution).

Mr D E Troy        Acquisition of 306 ADSs under the personal contribution element of the Plan.

Acquisition of 306 ADSs under the matching element of the Plan (Company contribution).

Dr P J T Vallance   Acquisition of 713 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 713 Ordinary Shares under the matching element of the Plan (Company contribution).

Ms E Walmsley     Acquisition of 284 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 284 Ordinary Shares under the matching element of the Plan (Company contribution).

The notional dividends accrued will be paid out in proportion to the percentage of the participant's deferred annual bonus holdings that will vest following the end of the relevant measurement period.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

S M Bicknell  
Company Secretary

11 October 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: October 11, 2013

By: SIMON BICKNELL  
-----

Simon Bicknell  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc